Top

Published in:

01-12-2019 | Neurofibromatosis | Clinical Study

Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live‑video randomized control trial

Authors: Jonathan Greenberg, Sarah Carter, Ethan Lester, Christopher J. Funes, Eric A. Macklin, Scott Plotkin, Ana-Maria Vranceanu

Published in: Journal of Neuro-Oncology | Issue 3/2019

Abstract

Introduction

Patients with NF2 who are deaf or have significant hearing loss face numerous and unique challenges which lead to poor quality of life, and thus may benefit from resiliency programs.

Methods

We performed secondary data analyses on a single blind, randomized controlled trial of an 8 week mind–body resiliency program (the Relaxation Response and Resiliency program for Deaf NF2; d3RP-NF2) versus a health education control (Health Enhancement Program for Deaf NF2;dHEP-NF2) which showed improvement in quality of life (Funes in JAMA 2019, https://doi.org/10.1007/s11060-019-03182-3). Here we report on improvements in resiliency factors (i.e. optimism, gratitude, perceived social support, mindfulness, and perceived coping abilities) assessed at baseline, post-test and 6-month follow-up. Both programs were delivered via Skype using Communication Access Real-Time Translation.

Results

Patients who were randomized to the d3RP-NF2 program exhibited significant improvements from baseline to post-program in gratitude (M_difference = 4.04, 95% CI 1.58–6.50; p = 0.002), perceived social support (M_difference = 16.36, 95% CI 9.20–23.51; p < 0.001), mindfulness (M_difference = 4.02, 95% CI 1.10–6.94; p = 0.008), perceived coping (M_difference = 15.25, 95% CI 10.21–20.28; p < 0.001), and a non-significant trend of improvement in optimism (M_difference = 1.15, 95% CI −0.14–12.44; p = 0.079). These improvements were all maintained through the 6-month follow up. Improvements in perceived coping (M_difference = 12.34, 95% CI 4.75–19.93; p = 0.002), social support (M_difference = 13.11, 95% CI 2.19–24.03; p = 0.02), and gratitude (M_difference = 4.59, 95% CI 0.83–8.36; p = 0.018) were over and above the changes observed in those randomized to dHEP-NF2.

Conclusion

The d3RP-NF2 sustainably improves multiple dimensions of resiliency. Promoting resiliency may be of utmost importance for this uderserved population.

Bonanno G, Galea S, Bucciarelli A, Vlahov D (2007) What predicts psychological resilience after disaster? The role of demographics, resources, and life stress. J Consult Clin Psychol 75(5):671–682CrossRefPubMed

Browne RH (1995) On the use of a pilot sample for sample size determination. Stat Med 14(17):1933–1940CrossRefPubMed

Carver CS (2006) MOCS (Measure of current status). Retrieved 19 June 2019 https://www.psy.miami.edu/faculty/ccarver/sclMOCS.html

Evans DGR (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4(1):16CrossRefPubMedPubMedCentral

Feldman G, Hayes A, Kumar S, Greeson J, Laurenceau JP (2007) Mindfulness and emotion regulation: the development and initial validation of the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R). J Psychopathol Behav Assess 29(3):177–190. https://doi.org/10.1007/s10862-006-9035-8 CrossRef

Fiol CM, O’Connor EJ (2013) In the waking up ! mindfulness face of bandwagons. Acad Manag Rev 28(1):54–70CrossRef

Funes CJ, Mace RA, Macklin EA, Plotkin SR, Jordan JT, Vranceanu AM (2019) First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. J Neurooncol. https://doi.org/10.1007/s11060-019-03182-3 CrossRefPubMed

Furnham A, Henderson M (1982) The good, the bad and the mad: response bias in self-report measures. Pers Individ Differ 3(3):311–320. https://doi.org/10.1016/0191-8869(82)90051-4 CrossRef

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. https://doi.org/10.1016/j.jbi.2008.08.010 CrossRefPubMed

10.

Horton TV, Wallander JL (2001) Hope and social support as resilience factors against psychological distress of mothers who care for children with chronic physical conditions. Rehabil Psychol 46(4):382–399. https://doi.org/10.1037/0090-5550.46.4.382 CrossRef

11.

Lachin JM (2000) Statistical considerations in the intent-to-treat principle. Control Clin Trials 21(3):167–189. https://doi.org/10.1016/S0197-2456(00)00046-5 CrossRefPubMed

12.

Lancaster GA, Dodd S, Williamson PR (2004) Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Prac. https://doi.org/10.1111/j.2002.384.doc.x CrossRef

13.

McCullough ME, Emmons RA, Tsang JA (2002) The grateful disposition: a conceptual and empirical topography. J Pers Soc Psychol 82(1):112–127. https://doi.org/10.1037/0022-3514.82.1.112 CrossRefPubMed

14.

Merker VL, Bergner AL, Vranceanu A-M, Muzikansky A, Slattery W, Plotkin SR (2016) Health-related quality of life of individuals with neurofibromatosis type 2. Otol Neurotol 37(5):574–579. https://doi.org/10.1097/mao.0000000000001019 CrossRefPubMed

15.

Mortel TF (2008) Faking it: social desirability response bias in self-report research. Aust J Adv Nurs 25(4):40–48

16.

Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DGR (2010) The relationship between patients’ perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35(4):291–299. https://doi.org/10.1111/j.1749-4486.2010.02176.x CrossRefPubMed

17.

Page PZ, Page GP, Ecosse E, Korf BM, Leplege A, Wolkenstein P (2006) Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet Part A 140(18):1893–1898. https://doi.org/10.1002/ajmg.a.31422 CrossRefPubMed

18.

Scheier MF, Carver CS (1985) Optimism, coping, and health: assessment and implications of generalized outcome expectancies. Health Psychol 4(3):219–247. https://doi.org/10.1037/0278-6133.4.3.219 CrossRefPubMed

19.

Scheier MF, Carver CS, Bridges MW (1994) Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. J Pers Soc Psychol 67(6):1063–1078. https://doi.org/10.1037/0022-3514.67.6.1063 CrossRefPubMed

20.

Sherbourne CD, Stewart AL (1991) The MOS social support survey. Soc Sci Med 32(6):705–714. https://doi.org/10.1016/0277-9536(91)90150-B CrossRefPubMed

21.

Shih WJ, Ohman-Strickland PO, Lin Y (2004) Analysis of pilot and early phase studies with small sample sizes. Stat Med 23(12):1827–1842. https://doi.org/10.1002/sim.1807 CrossRefPubMed

22.

Steinhardt M, Dolbier C (2008) Evaluation of a resilience intervention to enhance coping strategies and protective factors and decrease symptomatology. J Am Coll Health 56(4):445–453. https://doi.org/10.3200/JACH.56.44.445-454 CrossRefPubMed

23.

Tait L, Birchwood M, Trower P (2004) Adapting to the challenge of psychosis: Personal resilience and the use of sealing-over (avoidant) coping strategies. Br J Psychiatry 185(5):410–415CrossRefPubMed

24.

Thompson RW, Arnkoff DB, Glass CR (2011) Conceptualizing mindfulness and acceptance as components of psychological resilience to trauma. Trauma, Violence, Abuse 12(4):220–235. https://doi.org/10.1177/1524838011416375 CrossRefPubMed

25.

Vranceanu AM, Merker VL, Park E, Plotkin SR (2013) Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. https://doi.org/10.1007/s11060-013-1195-2 CrossRefPubMed

26.

Vranceanu AM, Merker VL, Plotkin SR, Park ER (2014) The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol 120(1):103–109. https://doi.org/10.1007/s11060-014-1522-2 CrossRefPubMed

27.

Vranceanu AM, Riklin E, Merker VL, Macklin EA, Park ER, Plotkin SR (2016) Mind-body therapy via videoconferencing in patients with neurofibromatosis: an RCT. Neurology 87(8):806–814. https://doi.org/10.1212/WNL.0000000000003005 CrossRefPubMed

28.

Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, Plotkin SR (2012) Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med 14(12):977–982. https://doi.org/10.1038/gim.2012.85 CrossRefPubMedPubMedCentral

29.

Windle G (2011) What is resilience? A review and concept analysis. Rev Clin Gerontol 21(2):152–169CrossRef

30.

Zale EL, Pierre-Louis C, Macklin EA, Riklin E, Vranceanu AM (2018) The impact of a mind–body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis. J Neurooncol 137(2):321–329. https://doi.org/10.1007/s11060-017-2720-5 CrossRefPubMed

Title: Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live‑video randomized control trial
Authors: Jonathan Greenberg
Sarah Carter
Ethan Lester
Christopher J. Funes
Eric A. Macklin
Scott Plotkin
Ana-Maria Vranceanu
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Neurofibromatosis
Neurofibromatosis
Published in: Journal of Neuro-Oncology / Issue 3/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03326-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live‑video randomized control trial

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Increased 14C-acetate accumulation in IDH-mutated human glioblastoma: implications for detecting IDH-mutated glioblastoma with 11C-acetate PET imaging

Extent of surrounding edema does not correlate with acute complications after radiosurgery for melanoma brain metastases

Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification

Surgical and radiosurgical treatment strategies for Cushing’s disease

Correction to: Efficacy of Dabrafenib for three children with brainstem BRAFV600E positive ganglioglioma

Association between extent of resection on survival in adult brainstem high-grade glioma patients